University of Liverpool: New funding, collaboration help AI-Sight advance its technology

AI-Sight, the AI diagnostic technology spin-out of the University of Liverpool has successfully completed its equity funding round from investors and industry figures.

Study in UK: The AI diagnostic technology spin-out, AI-Sight at the University of Liverpool has concluded its equity funding round from investors and healthcare industry figures.

The names of the funders include Phil Kirby (former Managing Director of InHealth Intelligence), Sir Michael Bibby (Chairman of the Bibby Line Group and Hon PhD, University of Liverpool), Deepbridge Capital and Pitalia Capital (the family office of Anil Pitalia, Founder of SpaMedica).

Professor Simon Harding, Chief Medical Officer of AI-Sight, described the collaboration as: “An exciting opportunity that will allow us to test deployment of our AI technologies with one of the largest commercial suppliers of diabetic retinopathy screening in the UK and elsewhere, and add further external validation data for imminent regulatory submissions. Vision loss from diabetes is such a huge challenge throughout the world and prevention is only possible through organised screening. With the successful conclusion of our funding round, it is an exciting time for AI-Sight, advancing our ground-breaking technology towards allowing affordable screening programmes and a profound impact on the lives of people with diabetes worldwide.”

Dr Carolyn Horrocks, Head of Medtech & Bioscience Enterprise, The Enterprise Team, University of Liverpool, said, “The University is delighted by the continuing success of our spin-out company AI-Sight, not only in raising commercial investment, but also in establishing industry collaborations that are supporting further research at the University. This is a strong return on the University’s Enterprise Investment Fund’s initial investment commitment to support AI-Sight. The company’s continuing work to translate University research into technologies and products that can transform lives around the world is part of our commitment to fostering innovation, entrepreneurship and impact by our world class researchers.”

More Details

The collaboration of the University of Liverpool, AI-Sight and InHealth will allow for unique AI diagnostic technology and clinical studies.

Dr Andy Round, Investment Director at Deepbridge Capital, commented, “We are delighted to have supported another spin-out from the University of Liverpool. The exciting work being undertaken, and the significant progress being made, by AI Sight represent a great example of how a collaborative innovation ecosystem successfully spins out academic research into transformative technologies. Such collaborations also exemplify how Government initiatives, such as the Enterprise Investment Scheme and Seed Enterprise Investment Scheme, are encouraging private investment into such exciting technology innovations.  We look forward to continuing to support the AI Sight team and the University going forward.”

Read more:

• Study in UK: Apply for Oxford University's MSc In Digital Scholarship 2025
• UQ researchers bag Advance Queensland Industry Research Fellowships